Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2004 1
2005 2
2006 2
2007 4
2008 1
2009 5
2010 4
2011 3
2012 4
2013 9
2014 7
2015 8
2016 5
2017 6
2018 8
2019 10
2020 8
2021 8
2022 5
Text availability
Article attribute
Article type
Publication date

Search Results

94 results
Results by year
Filters applied: . Clear all
Page 1
Targeted protein degradation: expanding the toolbox.
Schapira M, Calabrese MF, Bullock AN, Crews CM. Schapira M, et al. Among authors: bullock an. Nat Rev Drug Discov. 2019 Dec;18(12):949-963. doi: 10.1038/s41573-019-0047-y. Epub 2019 Oct 30. Nat Rev Drug Discov. 2019. PMID: 31666732
Ubiquitin ligases: guardians of mammalian development.
Cruz Walma DA, Chen Z, Bullock AN, Yamada KM. Cruz Walma DA, et al. Among authors: bullock an. Nat Rev Mol Cell Biol. 2022 May;23(5):350-367. doi: 10.1038/s41580-021-00448-5. Epub 2022 Jan 25. Nat Rev Mol Cell Biol. 2022. PMID: 35079164 Review.
Human AGR2 Deficiency Causes Mucus Barrier Dysfunction and Infantile Inflammatory Bowel Disease.
Al-Shaibi AA, Abdel-Motal UM, Hubrack SZ, Bullock AN, Al-Marri AA, Agrebi N, Al-Subaiey AA, Ibrahim NA, Charles AK; COLORS in IBD-Qatar Study Group, Elawad M, Uhlig HH, Lo B. Al-Shaibi AA, et al. Among authors: bullock an. Cell Mol Gastroenterol Hepatol. 2021;12(5):1809-1830. doi: 10.1016/j.jcmgh.2021.07.001. Epub 2021 Jul 6. Cell Mol Gastroenterol Hepatol. 2021. PMID: 34237462 Free PMC article.
CIS is a potent checkpoint in NK cell-mediated tumor immunity.
Delconte RB, Kolesnik TB, Dagley LF, Rautela J, Shi W, Putz EM, Stannard K, Zhang JG, Teh C, Firth M, Ushiki T, Andoniou CE, Degli-Esposti MA, Sharp PP, Sanvitale CE, Infusini G, Liau NP, Linossi EM, Burns CJ, Carotta S, Gray DH, Seillet C, Hutchinson DS, Belz GT, Webb AI, Alexander WS, Li SS, Bullock AN, Babon JJ, Smyth MJ, Nicholson SE, Huntington ND. Delconte RB, et al. Among authors: bullock an. Nat Immunol. 2016 Jul;17(7):816-24. doi: 10.1038/ni.3470. Epub 2016 May 23. Nat Immunol. 2016. PMID: 27213690
Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors.
Zhang T, Kwiatkowski N, Olson CM, Dixon-Clarke SE, Abraham BJ, Greifenberg AK, Ficarro SB, Elkins JM, Liang Y, Hannett NM, Manz T, Hao M, Bartkowiak B, Greenleaf AL, Marto JA, Geyer M, Bullock AN, Young RA, Gray NS. Zhang T, et al. Among authors: bullock an. Nat Chem Biol. 2016 Oct;12(10):876-84. doi: 10.1038/nchembio.2166. Epub 2016 Aug 29. Nat Chem Biol. 2016. PMID: 27571479 Free PMC article.
Saracatinib is an efficacious clinical candidate for fibrodysplasia ossificans progressiva.
Williams E, Bagarova J, Kerr G, Xia DD, Place ES, Dey D, Shen Y, Bocobo GA, Mohedas AH, Huang X, Sanderson PE, Lee A, Zheng W, Economides AN, Smith JC, Yu PB, Bullock AN. Williams E, et al. Among authors: bullock an. JCI Insight. 2021 Apr 22;6(8):e95042. doi: 10.1172/jci.insight.95042. JCI Insight. 2021. PMID: 33705358 Free PMC article.
Structural basis of Keap1 interactions with Nrf2.
Canning P, Sorrell FJ, Bullock AN. Canning P, et al. Among authors: bullock an. Free Radic Biol Med. 2015 Nov;88(Pt B):101-107. doi: 10.1016/j.freeradbiomed.2015.05.034. Epub 2015 Jun 7. Free Radic Biol Med. 2015. PMID: 26057936 Free PMC article. Review.
ACVR1 mutations in DIPG: lessons learned from FOP.
Taylor KR, Vinci M, Bullock AN, Jones C. Taylor KR, et al. Among authors: bullock an. Cancer Res. 2014 Sep 1;74(17):4565-70. doi: 10.1158/0008-5472.CAN-14-1298. Epub 2014 Aug 18. Cancer Res. 2014. PMID: 25136070 Free PMC article. Review.
94 results